Raymond James Financial Inc. Takes $3.23 Million Position in CRISPR Therapeutics AG (NASDAQ:CRSP)

Raymond James Financial Inc. bought a new position in shares of CRISPR Therapeutics AG (NASDAQ:CRSP) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 82,095 shares of the company’s stock, valued at approximately $3,231,000. Raymond James Financial Inc. owned about 0.10% of CRISPR Therapeutics at the end of the most recent quarter.

Other large investors have also recently bought and sold shares of the company. Highline Wealth Partners LLC purchased a new position in shares of CRISPR Therapeutics during the fourth quarter valued at approximately $39,000. Western Pacific Wealth Management LP boosted its stake in shares of CRISPR Therapeutics by 100.0% in the fourth quarter. Western Pacific Wealth Management LP now owns 1,000 shares of the company’s stock valued at $39,000 after purchasing an additional 500 shares during the period. Wilmington Savings Fund Society FSB acquired a new position in shares of CRISPR Therapeutics in the third quarter worth about $40,000. Spire Wealth Management grew its position in shares of CRISPR Therapeutics by 303.7% during the fourth quarter. Spire Wealth Management now owns 1,970 shares of the company’s stock worth $78,000 after buying an additional 1,482 shares in the last quarter. Finally, MCF Advisors LLC acquired a new stake in shares of CRISPR Therapeutics in the 4th quarter valued at about $80,000. Institutional investors and hedge funds own 69.20% of the company’s stock.

Insider Activity at CRISPR Therapeutics

In other news, CEO Samarth Kulkarni sold 9,973 shares of the stock in a transaction on Tuesday, March 11th. The stock was sold at an average price of $42.42, for a total value of $423,054.66. Following the transaction, the chief executive officer now owns 180,890 shares of the company’s stock, valued at $7,673,353.80. This represents a 5.23 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, COO Julianne Bruno sold 1,198 shares of CRISPR Therapeutics stock in a transaction that occurred on Tuesday, March 11th. The stock was sold at an average price of $42.42, for a total transaction of $50,819.16. Following the transaction, the chief operating officer now directly owns 8,263 shares in the company, valued at $350,516.46. The trade was a 12.66 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 32,381 shares of company stock valued at $1,608,243 over the last ninety days. 4.10% of the stock is owned by insiders.

Analyst Ratings Changes

Several analysts have weighed in on CRSP shares. TD Cowen upgraded shares of CRISPR Therapeutics from a “sell” rating to a “hold” rating and set a $35.00 target price for the company in a research note on Wednesday, February 12th. Needham & Company LLC reiterated a “buy” rating and issued a $84.00 price objective on shares of CRISPR Therapeutics in a report on Wednesday, February 12th. StockNews.com raised shares of CRISPR Therapeutics to a “sell” rating in a report on Friday, March 21st. Truist Financial increased their price target on CRISPR Therapeutics from $100.00 to $120.00 and gave the company a “buy” rating in a research report on Wednesday, February 12th. Finally, Stifel Nicolaus reduced their price target on shares of CRISPR Therapeutics from $53.00 to $49.00 and set a “hold” rating for the company in a research report on Thursday, February 13th. Two analysts have rated the stock with a sell rating, nine have given a hold rating and eleven have given a buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $73.11.

CRISPR Therapeutics Price Performance

NASDAQ:CRSP opened at $38.04 on Friday. The company has a fifty day moving average price of $43.17 and a 200 day moving average price of $45.23. The stock has a market cap of $3.26 billion, a P/E ratio of -8.70 and a beta of 1.77. CRISPR Therapeutics AG has a one year low of $36.52 and a one year high of $70.12.

CRISPR Therapeutics (NASDAQ:CRSP) last released its quarterly earnings data on Tuesday, February 11th. The company reported ($0.44) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.15) by $0.71. CRISPR Therapeutics had a negative return on equity of 18.46% and a negative net margin of 981.54%. As a group, equities research analysts anticipate that CRISPR Therapeutics AG will post -5.16 EPS for the current year.

CRISPR Therapeutics Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.